RadNet (RDNT) Q4 2025 earnings review
Record Revenues and AI Expansion, But GAAP Profitability Lags
RadNet closed 2025 with accelerating momentum. Total Revenue hit a quarterly record of $547.7 million (+14.8% YoY), driven by a surge in high-margin advanced imaging volumes and strong Digital Health adoption. Adjusted EBITDA expanded 16.9% to $87.7 million. However, the top-line success did not translate into GAAP profits—Net Income reversed to a $0.6 million loss due to heavy one-time expenses, including a $6.5 million equipment disposal loss and $6.3 million in non-capitalized AI R&D. Despite the messy bottom line, 2026 guidance points to accelerating growth, supported by the newly announced acquisition of Gleamer to dominate the clinical AI space.
🐂 Bull Case
The lucrative advanced imaging segment (MRI, CT, PET/CT) is accelerating. Aggregate procedural volumes grew 14.1% YoY in Q4, boosting overall margins and proving the durability of the secular shift from hospitals to outpatient centers.
Digital Health segment revenue surged 48.2% in Q4 to $27.9 million. Annual Recurring Revenue (ARR) exited the year at $75.4 million, representing over 80% of segment sales, validating the shift toward a predictable software-as-a-service (SaaS) model.
🐻 Bear Case
While Digital Health revenue soared 48.2%, segment Adjusted EBITDA only grew 8.9%. Massive investments in infrastructure and non-capitalized R&D are severely compressing profitability in this division.
The company continues to report substantial one-time and unusual items. Severance, lease abandonments, transaction costs, and heavy R&D adjustments turned a fundamentally strong quarter into a GAAP net loss.
⚖️ Verdict: 🟢
Bullish. The core imaging business is a highly efficient cash-generating engine that is successfully pivoting toward high-margin advanced procedures. The GAAP loss is optically poor but heavily driven by strategic M&A and AI R&D that solidify RadNet's technological moat.
Key Themes
Advanced Imaging as the Core Growth Engine
RadNet's deliberate shift toward higher-margin modalities continues to pay off. In Q4, advanced imaging (MR, CT, PET/CT) increased its share of total procedure volume by 178 basis points YoY. PET/CT was the standout, accelerating to 28.3% YoY growth, driven by new oncology and neurology applications.
Aggressive AI M&A Rollup (Gleamer Acquisition)
Management is aggressively positioning RadNet as the preeminent global AI imaging company. The Q4 announcement of the Gleamer acquisition adds robust musculoskeletal AI capabilities to an already extensive portfolio (iCAD for breast, See-Mode for thyroid). The company now targets at least four FDA clearances in 2026.
Digital Health Profitability Drag
The financial profile of the Digital Health division requires close monitoring. Revenue is accelerating, but profitability is stable-to-decelerating due to heavy R&D and commercial infrastructure spending. Q4 Digital Health revenue grew $9.1 million YoY, but EBITDA only grew $0.4 million. 2026 guidance projects $135-145 million in segment revenue but only $10-12 million in Adjusted EBITDA—a margin of less than 9%.
Tech-Enabled Capacity & Throughput
RadNet is successfully deploying its proprietary software (TechLive and AI clinical tools) to combat industry-wide labor shortages. These tools automate manual processes, expand operating hours, and decrease scan times. This operational leverage allowed same-center volumes to grow 4.5% in Q4, directly fueling the 29 bps improvement in consolidated Adjusted EBITDA margins.
Other KPIs
ARR now represents 81.3% of total 2025 Digital Health revenue. This high concentration of recurring revenue indicates successful transition to a software-as-a-service model, improving revenue visibility and stickiness as the company integrates its AI acquisitions.
Decelerating slightly from $0.24 in 24Q4. To arrive at this number, management added back over $18.6 million in adjustments, including equipment disposal losses, transaction costs, and a massive $5.7 million tax provision adjustment to normalize the rate.
Accelerating. Same-center growth remains extremely healthy, particularly in Advanced Imaging which grew 9.6%. This indicates RadNet is capturing market share and increasing throughput at existing facilities without requiring de novo capital expenditure.
Guidance
Accelerating. The midpoint of $2,350 million implies a massive 18% YoY growth from 2025. This assumes continued same-center volume growth, favorable reimbursement pricing, and aggressive contribution from both de novo openings and tuck-in acquisitions.
Accelerating. Implies roughly 51% YoY growth at the midpoint. Notably, management expects the portion of this revenue coming internally from RadNet's own imaging centers to decline from 45% to 33%, signaling significant traction with external third-party software sales.
Accelerating. Represents exceptional 29% to 41% YoY growth. This robust cash generation easily funds the projected $165-$175 million in capital expenditures while providing ample liquidity for debt service and continued M&A.
Key Questions
Gleamer Integration Timeline
With the Gleamer acquisition adding MSK AI to your portfolio, what is the timeline for internal rollout across RadNet centers, and how soon will we see material third-party cross-selling synergies?
Digital Health Margin Floor
Digital Health revenue is guided up ~50% in 2026, but EBITDA guidance remains compressed at $10-$12 million. When do you expect the infrastructure investments to peak and allow this segment to demonstrate standard SaaS-like operating leverage?
TechLive Capacity Ceiling
TechLive has been a clear driver of expanded capacity and margin improvement. What percentage of your advanced imaging fleet is currently utilizing TechLive, and how much remaining 'hidden capacity' is left to unlock?